Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Hepatitis B can lead to liver disease. But we can prevent and manage this viral infection. Here’s what we know about the ...

The data included results from a Phase 3 study on Biktarvy’s efficacy in treating HIV and HBV co-infection, a Phase 2 study on a long-acting treatment regimen, and findings from the first HIV ...

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and ...

The data included results from a Phase 3 study on Biktarvy’s efficacy in treating HIV and HBV co-infection, a Phase 2 study on a long-acting treatment regimen, and findings from the first HIV cure ...

The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...

Enrollment in MAD portion of the trial continues with higher doses being evaluated OXFORDSHIRE, UK & CONSHOHOCKEN, PA & GAITHERSBURG, MD, USA I March 10, 2025 I Immunocore Holdings plc (Nasdaq: IMCR) ...

The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...